Brief: Active Biotech: New Data On Laquinimod From Phase 2 LEGATO-HD Study

Active Biotech AB publ

23/09/2019 08:07

Sept 23 (Reuters) - Active Biotech AB  ACTI.ST :
    * REG-ACTIVE BIOTECH: NEW DATA ON LAQUINIMOD FROM THE PHASE
2
LEGATO-HD STUDY IN HUNTINGTON’S DISEASE WILL BE PRESENTED AT THE
INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT
DISORDERS
    * PRIMARY ENDPOINT EVALUATING CHANGE FROM BASELINE AT MONTH
12 IN
UHDRS-TMS FOR 1.0 MG DOSE AS COMPARED WITH PLACEBO WAS NOT
ACHIEVED
    * SECONDARY ENDPOINT, PERCENT CHANGE IN BRAIN ATROPHY
(CAUDATE
VOLUME) FROM BASELINE AT 12 MONTHS IN 1.0 MG DOSE AS COMPARED TO
PLACEBO, WAS MET
    * SAFETY PROFILE IN STUDY WAS SIMILAR TO THAT EXPECTED IN
PATIENT
POPULATION

Source text for Eikon:  ID:nGNEPKScR 
Further company coverage:  ACTI.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))